Company Performance - iRadimed reported quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.45 per share, but showing an increase from $0.39 per share a year ago, resulting in an earnings surprise of -2.22% [1] - The company posted revenues of $19.39 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.57% and increasing from $17.45 million year-over-year [2] - Over the last four quarters, iRadimed has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - iRadimed shares have gained about 10% since the beginning of the year, outperforming the S&P 500's gain of 2.9% [3] - The current consensus EPS estimate for the coming quarter is $0.42 on revenues of $19.46 million, and for the current fiscal year, it is $1.72 on revenues of $80.81 million [7] - The estimate revisions trend for iRadimed is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which iRadimed belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Results - iRadimed Corporation announced preliminary unaudited revenues for Q4 2024 and full-year 2024 on January 10, 2025[4] - The press release regarding the financial results is furnished as Exhibit 99.1 to the Current Report on Form 8-K[4] Company Information - The company is listed on the NASDAQ Capital Market under the trading symbol IRMD[3]

Core Insights - IRADIMED CORPORATION reported record financial results for Q4 2024, marking the fourteenth consecutive quarter of revenue growth, driven by strong demand for its MRI-compatible IV infusion pumps and patient monitoring systems [2][5][8] - The company announced an increase in its quarterly cash dividend from $0.15 to $0.17 per share, reflecting its strong financial position and commitment to returning value to shareholders [2][4] - For 2025, the company expects revenue between $78.0 million and $82.0 million, with GAAP diluted earnings per share projected between $1.55 and $1.65 [3][14] Financial Performance - For Q4 2024, the company reported revenue of $19.4 million, an increase of 11% from $17.5 million in Q4 2023, and net income of $5.1 million, up 13% from $4.5 million in the same period last year [5][8] - For the full year 2024, total revenue reached $73.2 million, a 12% increase from $65.6 million in 2023, with net income also rising by 12% to $19.2 million [7][9] - Non-GAAP net income for Q4 2024 was $5.7 million, a 14% increase from $5.0 million in Q4 2023, with non-GAAP diluted earnings per share at $0.44, up 13% [6][40] Revenue Breakdown - In Q4 2024, the revenue from MRI-compatible IV infusion pump systems was $7.57 million, up from $5.64 million in Q4 2023, while revenue from MRI-compatible patient vital signs monitoring systems was $6.57 million, slightly down from $6.85 million [10] - For the full year 2024, the revenue from IV infusion pump systems was $26.6 million, compared to $19.6 million in 2023, while monitoring systems generated $24.4 million, down from $25.4 million [10][11] Cash Flow and Investments - Cash flow from operations for Q4 2024 was $6.0 million, a 54% increase from $3.9 million in Q4 2023, and for the full year, it was $25.6 million, a 90% increase from $13.5 million [12][12] - The company is investing approximately $5.5 million in cash in 2025 to complete the construction of a new facility in Orlando, Florida, which is expected to support future growth [13] Guidance and Future Outlook - The company anticipates revenue for Q1 2025 to be between $19.2 million and $19.4 million, with GAAP diluted earnings per share expected to be between $0.35 and $0.39 [3][14] - The guidance for non-GAAP diluted earnings per share for 2025 is projected to be between $1.71 and $1.81 [14][15]

Core Viewpoint - Iradimed Corporation is set to release its 2024 fourth quarter financial results on February 13, 2025, and will host a conference call to discuss these results [1][2]. Company Overview - Iradimed Corporation specializes in developing innovative MRI-compatible medical devices, notably a non-magnetic intravenous infusion pump system designed for safe use during MRI procedures [3]. - The company was the first to create an infusion delivery system that mitigates risks associated with standard infusion pumps, which contain magnetic components that can interfere with MRI operations [3]. - The patented MRidium® MRI-compatible IV infusion pump utilizes a non-magnetic ultrasonic motor and non-ferrous parts to ensure safe and reliable delivery of anesthesia and IV fluids during MRI scans [3]. Product Features - The Iradimed 3880 MRI-compatible patient vital signs monitoring system is designed with non-magnetic components, allowing it to function in magnetic fields up to 30,000 gauss, ensuring patient safety during MRI procedures [4]. - This system features wireless ECG, SpO2 monitoring, non-magnetic respiratory CO2 measurement, and both invasive and non-invasive blood pressure monitoring, among other capabilities [4]. - The compact and lightweight design of the Iradimed 3880 allows for continuous monitoring of critically ill patients, reducing the time they spend away from critical care units [4].

Core Insights - Iradimed Corporation reported preliminary unaudited revenue for Q4 and full-year 2024, indicating strong growth and record-breaking performance [2][3][7] - The company anticipates Q4 2024 revenue between $19.2 million and $19.4 million, reflecting a year-over-year growth of 10% to 11% and a sequential growth of 5% to 6% [2][7] - Full-year 2024 revenue is expected to be approximately $73.1 million to $73.3 million, compared to $65.6 million in the previous year, representing an 11% to 12% year-over-year growth [2][7] Financial Performance - Q4 2024 revenue is projected to be the highest quarterly revenue to date for the company, marking the 14th consecutive quarter of record revenues [3] - Orders booked in Q4 2024 exceeded shipments, resulting in a robust backlog and enhanced visibility for 2025 [3] Product Offerings - Iradimed is a leader in developing MRI-compatible medical devices, including the MRidium® MRI compatible IV infusion pump system and the 3880 MRI-compatible patient vital signs monitoring system [4][5][6] - The MRidium® system is designed to safely deliver anesthesia and IV fluids during MRI procedures, addressing safety concerns associated with standard infusion pumps [5] - The 3880 system allows for continuous monitoring of vital signs in high magnetic fields, enhancing patient safety and care during MRI scans [6] Upcoming Events - The company is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 5:15 p.m. Pacific Time [3][7]

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock aliv ...

Company Overview - IRADIMED CORPORATION is a leading provider of innovative MRI-compatible medical devices and the only provider of a non-magnetic IV infusion pump system [3][4] - The company designs, manufactures, markets, and distributes MRI-compatible medical devices, accessories, disposables, and related services [3] Product Highlights - The MRidium® MRI-compatible IV infusion pump system features a non-magnetic ultrasonic motor and non-ferrous parts, designed to safely deliver anesthesia and IV fluids during MRI procedures [4] - The 3880 MRI-compatible patient vital signs monitoring system operates in magnetic fields up to 30,000 gauss, ensuring patient safety and uninterrupted monitoring during MRI scans [5] - The 3880 system includes features such as wireless ECG, wireless SpO2, non-magnetic respiratory CO2, and advanced multi-gas anesthetic agent unit [5] Upcoming Events - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 5:15 p.m. Pacific Time [2]

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for successful short-term investing, highlighting the utility of a specific screening strategy to identify stocks with strong fundamentals and positive price momentum [1][2]. Group 1: Investment Strategy - The "Recent Price Strength" screen is designed to identify stocks with sufficient fundamental strength to maintain their upward price trends, focusing on those trading in the upper portion of their 52-week high-low range, indicating bullishness [3]. - A solid price increase of 10.6% over 12 weeks for iRadimed (IRMD) reflects investor confidence in the stock's potential upside [4]. - A price increase of 0.7% over the past four weeks indicates that the upward trend for IRMD is still intact [5]. Group 2: Stock Performance Indicators - IRMD is currently trading at 80.2% of its 52-week high-low range, suggesting it may be on the verge of a breakout [6]. - The stock holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are critical for near-term price movements [6]. - The Average Broker Recommendation for IRMD is 1 (Strong Buy), indicating high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Additional Insights - The article suggests that the price trend for IRMD is unlikely to reverse soon, and encourages consideration of other stocks that meet the "Recent Price Strength" criteria for potential investment [8]. - The effectiveness of stock-picking strategies can be backtested using the Zacks Research Wizard, which includes successful stock-picking strategies [9].

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for successful short-term investing, highlighting that price movements should be supported by strong fundamentals and positive earnings estimates [1][2]. Group 1: Stock Performance - iRadimed (IRMD) has shown a solid price increase of 28.8% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also maintained a price increase of 13.8% over the last four weeks, suggesting that the upward trend is still intact [5]. - Currently, IRMD is trading at 94.9% of its 52-week high-low range, indicating a potential breakout [6]. Group 2: Fundamental Strength - IRMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The "Recent Price Strength" screen is a useful tool for investors to identify stocks like IRMD that are on an uptrend supported by strong fundamentals [3]. - The article suggests that there are several other stocks passing through this screen, providing additional investment opportunities [8].

Core Insights - Iradimed Corporation has been recognized as one of Fortune's 100 Fastest Growing Companies for 2024, ranking 61st on the list, which highlights the company's growth in revenue, profits, and stock returns [2] Company Overview - Iradimed Corporation specializes in developing innovative MRI-compatible medical devices, including a non-magnetic intravenous infusion pump system and patient vital signs monitoring systems designed for MRI procedures [4][5] - The company is the only known provider of a non-magnetic IV infusion pump system, which is crucial for safely delivering anesthesia and IV fluids during MRI procedures [5][6] Product Details - The MRidium® MRI-compatible IV infusion pump system features a non-magnetic ultrasonic motor and non-ferrous parts, ensuring safe operation in the presence of MRI's powerful magnetic fields [5] - The 3880 MRI-compatible patient vital signs monitoring system is designed to operate in magnetic fields up to 30,000 gauss, allowing for continuous monitoring of critically ill patients during MRI scans [7] - The 3880 system includes advanced features such as wireless ECG, SpO2 monitoring, non-magnetic respiratory CO2 measurement, and optional multi-gas anesthetic agent monitoring [7]